# Pediatrix Medical Group, Inc. (MD) Stock Analysis: A Stable Healthcare Play with Solid Free Cash Flow

- Link: https://www.directorstalkinterviews.com/pediatrix-medical-group-inc-md-stock-analysis-a-stable-healthcare-play-with-solid-free-cash-flow/4121266254
- Published: 2026-10-13T10:14:58+01:00
- Author: Madison Wilson

Pediatrix Medical Group, Inc. (NYSE: MD) operates in the healthcare sector, specifically
within the medical care facilities industry. With a market capitalization of $2.19
billion, this company plays a crucial role in providing specialized services such
as newborn, maternal-fetal, and pediatric subspecialty care across the United States.
The recent change in the company’s name from MEDNAX, Inc. to Pediatrix Medical Group,
Inc. in July 2022 marked a pivotal rebranding effort, reflecting its focus on pediatric
healthcare services.

Currently, Pediatrix’s stock is priced at $26.92, hovering near the upper end of
its 52-week range of $16.05 to $27.39. This price stability is bolstered by a 50-
day moving average of $26.35 and a 200-day moving average of $23.42. The stock’s
RSI (Relative Strength Index) of 62.99 suggests it’s approaching overbought territory,
indicating robust investor interest.

Despite Pediatrix’s solid market position, the company does not pay dividends, with
a dividend yield and payout ratio both at 0.00%. This may deter income-focused investors,
but those looking for growth potential may find solace in its financial performance
metrics. The company boasts a revenue growth of 4.00% and an EPS (Earnings Per Share)
of $2.09, supported by a commendable return on equity of 20.39%. Notably, Pediatrix
has demonstrated strong cash generation capabilities, with a free cash flow amounting
to over $160 million, underscoring its financial health and ability to reinvest 
in growth initiatives.

Valuation metrics present a mixed picture. The forward P/E ratio stands at 11.03,
which may be appealing to investors seeking undervalued opportunities in the healthcare
sector. However, the absence of a trailing P/E ratio, PEG ratio, and price-to-book
ratio suggests that investors should approach with caution and conduct further due
diligence.

Analyst sentiment towards Pediatrix is predominantly neutral, with one buy rating
and six hold ratings. The target price range of $21.00 to $28.00, with an average
target of $26.33, indicates potential downside of approximately 2.18% based on the
current price. This suggests that while the stock might not have significant upside
potential in the short term, it remains a stable investment in the long run.

From a technical standpoint, the MACD (Moving Average Convergence Divergence) indicator
of 0.02 alongside a signal line of -0.08 implies that the stock is exhibiting a 
bullish trend, albeit with cautious optimism.

As Pediatrix Medical Group continues to navigate the healthcare landscape with its
specialized services, investors should consider its stable financial position, strong
free cash flow, and strategic focus on pediatric care. While the stock’s growth 
prospects appear modest, its robust operational framework and committed focus on
specialized healthcare services position it as a potentially reliable player within
the healthcare investment space.

Share on:
